Riskpilot← Back to searchSign inGet full accessRPS RESEARCH NORWAY AS
ASActiveOrg 994115405Dronning Mauds Gate 15, 0250 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 200926 employees
Revenue 2024
NOK 34,1M
-3% vs 2023
EBITDA margin
6.5%
-1% vs 2023
Equity ratio
66.1%
Financial strength
Net profit 2024
NOK 1,6M
+55% vs 2023
| Revenue | NOK 34,1M | -3% |
| EBITDA | NOK 2,2M | -1% |
| Net profit | NOK 1,6M | +55% |
| Total assets | NOK 16,5M | +10% |
| Equity | NOK 10,9M | +17% |
| Employees | 26 | — |
Legal name
RPS RESEARCH NORWAY AS
Org number
994115405
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25. mai 2009
Share capital
NOK 100 000
Employees
26 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Å tilby tjenester innen farmasøytisk industri og forskning, og alt som står i forbindelse med dette.
Address
Dronning Mauds Gate 15, 0250 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 19 697 | 20 682 | 26 591 | 35 170 | 34 142 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 1 218 | 1 283 | 1 875 | 2 233 | 2 210 |
| Depreciation & amort. | −16 | −21 | −16 | −9 | −1 |
| EBIT | 1 202 | 1 262 | 1 859 | 2 224 | 2 209 |
| Net financials | −44 | 82 | −274 | −875 | −150 |
| Profit before tax | 1 158 | 1 345 | 1 585 | 1 349 | 2 059 |
| Tax | 256 | −0 | −0 | −0 | −0 |
| Net profit | 902 | 1 049 | 1 231 | 1 037 | 1 607 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 20 892 | 11 193 | 12 812 | 15 063 | 16 528 |
| Equity | 6 007 | 7 055 | 8 287 | 9 324 | 10 931 |
| Long-term debt | 12 321 | 1 047 | 1 214 | 1 346 | 0 |
| Short-term debt | 2 564 | 3 090 | 3 311 | 4 394 | 5 597 |
| Total debt | 14 885 | 4 138 | 4 526 | 5 739 | 5 597 |
EBITDA margin
6.5%
This company
15.8%
Market median
-59% vs market
20202024
Equity ratio
66.1%
This company
38.2%
Market median
+73% vs market
20202024
Return on equity
14.7%
This company
18.4%
Market median
+20% vs market
20202024
Net profit margin
4.7%
This company
8.1%
Market median
-42% vs market
20202024
Asset turnover
2.07×
This company
1.12×
Market median
+85% vs market
20202024
Debt / equity
0.51×
This company
0.62×
Market median
+18% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AG Contact Person | Contact Person | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (2) | ||
| Chairman | 2023 – 2023 | |
| Board of Directors | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Research Pharmaceutical Services Ne | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RPS RESEARCH NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Granrud Helset | Contact Person | 0 companies |
| Samir Dilip Shah | Chairman | 0 companies |
| John Sheahan | Board of Directors | 0 companies |
| Barry Edward Balfe | Chairman | 0 companies |
| Grigore-Marian Voinov | Board of Directors | 0 companies |